Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 29

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 29
---
 the date of this prospectus, while information that we file later with the SEC will automatically
update and supersede the information in this prospectus to the extent that a statement contained in this prospectus or free writing prospectus
provided to you in connection with this offering, or in any other document we subsequently file with the SEC that also is incorporated
by reference in this prospectus, modifies or supersedes the original statement.

The following documents, which we have filed with
the SEC are incorporated by reference in this prospectus:

<div align='center'>S-22</div>

| · 
 · | our quarterly reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025, and September 30, 2025 filed with the SEC on May 14, 2025, August 12, 2025, and November 12, 2025, respectively;                                           
 our Current Reports on Form 8-K, filed with the SEC on March 12, 2025, April 2, 2025, May 1, 2025, June 13, 2025, and August 12, 2025 (only with respect to information filed under Items 1.01, 2.03, and 9.01 of such Current Report on Form 8-K); |
|:--|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| · | the portions of our Definitive Proxy Statement on Schedule 14A that are deemed to have been “filed” with the SEC on April 28, 2025;                                                                                                                 |
| · | the description of our common stock contained in our registration statement on Form 8-A, filed with the SEC on August 18, 2015, including all amendments and reports filed for the purpose of updating such description.                            |

All documents subsequently filed by us pursuant
to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act after the date of this prospectus supplement and prior to the termination
of all offerings covered by this prospectus supplement hereby shall be deemed to be incorporated by reference in this prospectus supplement
and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed
to have been furnished and not filed in accordance with SEC rules shall not be deemed incorporated by reference into this prospectus
supplement.

Any statement contained herein or in a